Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR5A | P47898 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22412381 | 0.98 | CDC7 (0.58) | CDC7CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29539832 | 0.87 | PDGFRB (0.55) | CDC7ROCK2HTR3EHTR3BHTR3A | |
| SCHEMBL2799745 | 0.87 | PDGFRB (0.55) | CDC7ROCK2HTR3EHTR3BHTR3A | |
| SCHEMBL15515501 | 0.87 | CYP3A4 (0.58) | CYP3A4ROCK2ROCK1 | |
| SCHEMBL24172739 | 0.87 | CYP3A4 (0.58) | CYP2D6SLC6A2SLC6A4SLC6A3CYP3A4 | |
| Tert-Butyl Formate SCHEMBL27665780 | 0.85 | CDC7 (0.50) | CDC7CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5412781 | 0.83 | PLK4 (0.56) | CYP2D6SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL5823182 | 0.80 | CYP3A4 (0.55) | CYP2D6SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL30905935 | 0.79 | HTR3E (0.49) | CDC7CYP2D6SLC6A4CYP3A4HTR3E | |
| SCHEMBL24421947 | 0.79 | CYP3A4 (0.57) | CYP2D6SLC6A2SLC6A4SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | CDC7 2568/4885CYP2D6 1675/4885SLC6A2 518/4885 |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | CDC7 64/4885CYP2D6 3575/4885SLC6A2 4631/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | CDC7 1951/4885CYP2D6 425/4885SLC6A2 2510/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | CDC7 64/4885CYP2D6 3575/4885SLC6A2 4631/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | CDC7 754/4885CYP2D6 3216/4885SLC6A2 3892/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | CDC7 64/4885CYP2D6 3575/4885SLC6A2 4631/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | CDC7 101/4885CYP2D6 4499/4885SLC6A2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.